or
Remember me
Back
eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
2024-04-04 05:30 PT - News Release
Receive investor kits and email updates from Stockhouse and directly from these companies.